GMED

As of 2026-10-26, GMED scores 50out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. GMED trades at $81.83, within its fair-value band.

GMED scores 50 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 50. Its strongest factor is value at 80 (exceptional), where it screens cheap on the model's valuation inputs, followed by quality at 47. The weakest is momentum at 39, where price trend is the soft spot. Among Healthcare stocks it sits in the lower 49% of Healthcare names by composite.

On valuation, GMED is priced near the floor of its own recent range — the cheap end on the model's valuation read. The blended composite before the macro overlay was 51. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on GMED, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where GMED sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for GMED runs $79.72–$116.71. Current price $81.83 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.